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ABSTRACT
Objective: This study evaluated the effect of home
oxygen therapy (HOT) on hospital admissions in chronic
obstructive pulmonary disease (COPD) patients.
Design and setting: Using nationwide health insurance
claims from 2002–2012, we conducted a longitudinal
population-based retrospective cohort study.
Participants: Individuals who were aged 40 years or
above and newly diagnosed with COPD in 2005.
Outcome measures: The primary outcome was total
number of hospitalisations during the study period.
Participants were matched using HOT propensity scores
and were stratified by respiratory impairment (grade 1:
FEV1 ≤25% or PaO2 ≤55 mm Hg; grade 2: FEV1 ≤30%
or PaO2 56–60 mm Hg; grade 3: FEV1 ≤40% or PaO2
61–65 mm Hg; ‘no grade’: FEV1 or PaO2 unknown), then
a negative binomial regression analysis was performed
for each group.
Results: Of the 36 761 COPD patients included in our
study, 1330 (3.6%) received HOT. In a multivariate
analysis of grade 1 patients performed before propensity
score matching, the adjusted relative risk of
hospitalisation for patients who did not receive HOT was
1.27 (95% CI 1.01 to 1.60). In a multivariate analysis of
grade 1 patients performed after matching, the adjusted
relative risk for patients who did not receive HOT was 1.65
(95% CI 1.25 to 2.18). In grade 2 or grade 3 patients, no
statistical difference in hospital admission risk was
detected. In the ‘no grade’ group of patients, HOT was
associated with an increased risk of hospitalisation.
Conclusions: HOT reduces the risk of hospital
admission in COPD patients with severe hypoxaemia.
However, apart from these patients, HOT use is not
associated with hospital admissions.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is a common frequently undiag-
nosed disease characterised by progressive
airﬂow limitation that is not fully reversible,
causing disability.1 COPD is a major cause of
morbidity and mortality, responsible for an
increasing and substantial societal burden,2
and hence is viewed as a serious public
health problem in many countries.
According to WHO estimates, 80 million
people have moderate to severe COPD, and
3 million people died of COPD in 2005. The
same estimates also predicted that it will
become the fourth leading cause of death by
2030.3
In an effort to combat COPD-related hos-
pitalisation, researchers have studied the
effects of oxygen therapy. Long-term oxygen
therapy (LTOT) has been shown to improve
survival and quality of life as well as to stabil-
ise pulmonary hypertension in COPD
patients.4–9 In Korea, clinical practitioners
and policy-makers have begun to recognise
the beneﬁts of LTOT. Social welfare services
are offered home oxygen therapy to those
with respiratory related disabilities for free.10
Home oxygen therapy (HOT) is the adminis-
tration at home of oxygen at concentrations
Strengths and limitations of this study
▪ We analysed the association between home
oxygen therapy and hospitalisation for chronic
obstructive pulmonary disease patients using
nationwide claims data and conducted a longitu-
dinal population-based prospective analysis
based on claims from 2005 to 2012.
▪ We were able to increase the homogeneity of our
study sample by identifying patients who were
newly diagnosed in 2005.
▪ We made an effort to accurately determine the
net effect of home oxygen therapy via propensity
score matching.
▪ Our findings may have potential unmeasured
variable bias because we used data based on
claims.
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greater than the ambient air concentration and has
been covered by the Korean national health insurance
system since 2006. However, ambulatory oxygen delivery
systems and home ventilator services are not currently
covered by the health insurance system. As the burden
of COPD continues to increase, analysing the status of
healthcare utilisation in patients with COPD is important
for establishing healthcare plans that encourage proper
management of COPD. These issues have been raised in
Korea as well as in many other countries where the
burden of COPD is increasing, so guidelines for the pro-
vision of HOT are needed.
However, ﬁndings concerning the effect of HOT on
hospitalisation have varied. Although several studies have
indicated that LTOT decreases hospital admissions,11–14
one study found no effect.15 Most studies that found
LTOT had an effect on hospital admission detected the
greatest association among severely hypoxemic COPD
patients (PaO2 ≤60 mmHg at rest on room air).11–14
However, in moderately hypoxemic COPD patients (PaO2
55–70 mmHg at rest on room air: 7.3–9.5 kPa), HOT
may not reduce hospitalisations.15 Also, regarding oxygen
prescription, hospital admission is more likely in LTOT
users and medical costs are increasing due to the
inappropriate use of oxygen.16
The aim of this study was to assess the effect of HOT
on hospital admissions in COPD patients stratiﬁed
according to forced expiratory volume 1 s or arterial
oxygen tension values, and to provide evidence on
appropriate indications for HOT.
METHODS
Data and study design
This study used 2002–2012 claims from the Korean
National Health Insurance Service (KNHIS) claims data-
base. We conducted a longitudinal population-based retro-
spective cohort study of newly diagnosed adult COPD
patients to investigate the association between HOT and
hospital admissions over a 7-year follow-up period.
Participants were 40 years of age or older with newly diag-
nosed COPD (International Classiﬁcation of Disease, 10th
edition (ICD-10) codes J43.x (emphysema) (except for
J43.0, McLeod’s syndrome) and J44.x (COPD)). A new
diagnosis was conﬁrmed by a lack of COPD-related claims
in 2002–2004 and the ﬁrst COPD-related claim in 2005.
The presence or absence of HOT was analysed from 2006
onwards, and hospital admissions were analysed from
2007 to 2012. If a patient died during the study period,
we observed hospital admissions until the time of death.
Ethics approval for this study was granted by the institu-
tional review board of the Graduate School of Public
Health, Yonsei University, Seoul, Korea.
Study population
We identiﬁed 1 538 711 individuals in 2002–2012 who
were aged 40 years or older and had COPD. Of these
patients, 138 680 received their diagnosis in 2005 and
were still alive in 2006. We modiﬁed the criteria used by
Kim et al17 to deﬁne COPD patients using claims data.
Hence COPD was deﬁned in this study by the following
criteria: (1) age ≥40 years; (2) ICD-10 codes for COPD
( J43.x (emphysema) (except for J43.0) and J44.x
(COPD)); and (3) use of one or more COPD medica-
tions at least twice per year. Unfortunately, we could not
review all prescriptions and thus replaced the third cri-
terion with having over four outpatient visits per year
due to COPD as the primary diagnosis. Since we
inferred COPD diagnoses from information contained
in the KNHIS claims database, we developed a process
to help identify participants who actually had COPD. We
excluded 101 919 patients consisting of 9566 who had
died by 2005 and 92 353 who had fewer than four out-
patient visits with COPD as the primary complaint, did
not receive HOT, and did not experience a hospital
admission due to COPD during 2006. The exclusion cri-
terion of less than four outpatient visits was based on a
previous study where COPD patients in 2009 had a
mean number of outpatient visits of 7.4; the mean
number of outpatient visits in 2005 was 3.2 in our
sample. Our ﬁnal study sample included 36 761 patients,
1330 who received HOT and 35 431 who did not.
Variables
The dependent variable in this study was the total
number of hospital admissions due to COPD during the
study period. We deﬁned hospital admission due to
COPD as the use of inpatient medical services for more
than 1 day and primary emphysema or COPD according
to ICD-10 codes J43.x (except for J43.0) or J44.x.
Covariates considered included age, sex, health insur-
ance status (national health insurance or medical aid),
the Charlson Comorbidity Index (0, 1 or 2+),18 HOT
(yes, no), use of the intensive care unit (ICU) (yes, no),
number of hospital admissions (0, 1 or 2+), and respira-
tory impairment (1, 2, 3 or ‘no grade’). In Korea, the
Ministry of Health and Welfare provides social welfare
services to disabled people through the Welfare of
Disabled Persons Act, but employs strict criteria due to a
lack of ﬁnances for disabled people. According to the
Welfare of Disabled Persons Act, the severity of respira-
tory impairment is determined according to dyspnoea,
predicted FEV1 and PaO2. The criteria for grade 1 were
chronic respiratory failure requiring oxygen therapy and
a predicted FEV1 of ≤25% or a resting PaO2 of
≤55 mm Hg (room air); grade 2 criteria were dyspnoea
when walking at home and a predicted FEV1 of ≤30%
or PaO2 of 56–60 mm Hg (room air); and grade 3 cri-
teria were with dyspnoea when walking at one’s own
pace on level ground and a predicted predicted FEV1 of
≤40% or PaO2 of 61–65 mm Hg (room air). We deﬁned
the ‘no grade’ group as patients with unknown pre-
dicted FEV1 or PaO2. Only the comorbidity component
of the Charlson Comorbidity Index was calculated. All
variables were measured at the 2006 baseline.
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Statistical analysis
First, the demographic characteristics of patients who
received HOT and those who did not were compared; the
χ2 test was used to assess categorical variables, and t tests
were used to assess continuous variables. Next, a non-
parsimonious multivariable logistic regression model was
used to estimate propensity scores for HOT. Propensity
score matching (PSM) is a statistical matching technique
that attempts to estimate the effect of a treatment, policy
or other intervention by accounting for the covariates that
predict treatment reception. The PSM allows one to
design and analyse an observational study so that it mimics
certain characteristics of a randomised controlled trial.19
We included the following in our propensity model: age,
sex, health insurance type, Charlson Comorbidity Index,
ICU use, number of hospital admissions in 2006, and
respiratory disability grade. The c-statistic for our propen-
sity model was 0.784. Subjects who received HOT were
matched on a one-to-one basis with those who did not. We
then stratiﬁed participants according to their respiratory
disability grade, based on hypoxemic status, and evaluated
the relationship between HOT and hospital admissions in
each group using a negative binomial regression analysis,
which was chosen due to over-dispersion. All analyses were
performed using SAS V.9.3.
RESULTS
Of the 36 761 patients in our study, 1330 (3.6%)
received HOT. Before PSM, baseline characteristics dif-
fered signiﬁcantly between patients who received HOT
and those who did not (table 1). However, after PSM
only the number of hospital admissions and respiratory
disability grade differed between the two groups.
Table 2 presents incidence (ID) rates for hospital
admission according to HOT usage. Before PSM, the ID
rate for grade 1 (predicted FEV1 ≤25% or PaO2
≤55 mm Hg) patients who received HOT was 0.60 versus
1.01 for those who did not. However, for grade 2 and
grade 3 patients (predicted FEV1 ≤30% or PaO2 56–
60 mm Hg and predicted FEV1 ≤40% or PaO2 61–
65 mm Hg) or those categorised as ‘no grade’ (pre-
dicted FEV1 or PaO2 unknown), the ID rate was higher
for those who received HOT than for those who did not
(0.61 vs 0.63; 0.47 vs 0.46; and 0.34 vs 0.05, respectively).
Similar results were obtained after PSM. For grade 1
patients, the ID rate was lower for patients who received
HOT than for those who did not (0.62 vs 0.79), while
for grades 2 and 3 or ‘no grade’, the ID rate was higher
for patients who received HOT (0.59 vs 0.37; 0.47 vs
0.23; and 0.34 vs 0.07, respectively).
Table 1 Baseline characteristics of the study sample, stratified according to use of home oxygen therapy
Characteristics
Before matching (N=36 761) After matching (1:1; N=2478)
Yes, n (%) No, n (%)
p Value
Yes, n (%) No, n (%)
p Value1330 (3.6) 35 431 (96.4) 1239 (50.0) 1239 (50.0)
Age (years), mean (SD) 67.1 (9.6) 63.8 (12.0) <0.0001 67.4 (9.7) 68.0 (9.9) 0.14
Sex
Male 964 (4.7) 19 353 (95.3) <0.0001 884 (49.2) 912 (50.8) 0.21
Female 367 (2.2) 16 078 (97.8) 355 (52.0) 327 (48.0)
Health insurance type
National health insurance 1279 (3.8) 32 645 (96.2) <0.0001 1188 (50.5) 1163 (49.5) 0.02
Medical aid 51 (1.8) 2786 (98.2) 51 (40.2) 76 (59.8)
Charlson Comorbidity Index*
0 692 (6.5) 9983 (93.5) <0.0001 628 (48.4) 670 (51.6) 0.13
1 62 (5.7) 1021 (94.3) 57 (47.1) 64 (52.9)
≥2 576 (2.3) 24 427 (97.7) 554 (52.3) 505 (47.7)
ICU use
Yes 11 (6.9) 148 (93.1) <0.0001 9 (39.1) 12 (60.9) 0.30
No 1319 (3.6) 35 283 (96.4) 1230 (50.1) 1225 (49.9)
Number of hospital admissions
0 1147 (3.5) 31 923 (96.5) <0.0001 1067 (51.5) 1004 (48.5) 0.002
1 127 (4.9) 2486 (95.1) 119 (40.6) 174 (59.4)
≥2 56 (5.2) 1022 (94.8) 53 (46.5) 61 (53.5)
Respiratory impairment rating
Grade 1 (predicted FEV1 ≤25%
or PaO2 ≤55 mm Hg)
163 (43.2) 214 (56.8) <0.0001 91 (43.1) 120 (56.9) 0.001
Grade 2 (predicted FEV1 ≤30%
or PaO2 ≤60 mm Hg)
121 (35.6) 219 (64.4) 102 (55.7) 81 (44.3)
Grade 3 (predicted FEV1 ≤40%
or PaO2 ≤65 mm Hg)
110 (26.6) 304 (73.4) 110 (61.1) 70 (38.9)
No grade 936 (2.6) 34 694 (97.4) 936 (49.2) 968 (50.8)
*Calculated comorbidity component; subtracted age scores.
ICU, intensive care unit.
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Table 3 presents the adjusted relative risk (RR) for
hospital admission before PSM. After controlling for all
covariates, the adjusted RR for grade 1 patients who did
not receive HOT compared to the reference group
(those who did receive HOT) was 1.12 (95% CI 1.01 to
1.60). The RR for grade 2 patients was 0.96, but this dif-
ference was not statistically signiﬁcant. In the grade 3
and ‘no grade’ groups, the adjusted RRs for patients
who did not receive HOT were less than 1 (RR, 0.74,
95% CI 0.58 to 0.93; and RR, 0.65, 95% CI 0.60 to 0.70,
respectively).
After PSM, the adjusted RR for grade 1 patients who
did not receive HOT was 1.65 (95% CI 1.25 to 2.18); in
grade 2 patients, the adjusted RR was 1.07 (95% CI, 0.80
to 1.43); in grade 3 patients, the adjusted RR was 0.72
(95% CI 0.51 to 1.02); and in patients without a grade,
the adjusted RR was 0.73 (95% CI 0.62 to 0.86) (table 4).
DISCUSSION
We found that HOT was associated with a 27%
decreased risk of hospitalisation in grade 1 COPD
patients (predicted FEV1 ≤25% or PaO2 ≤55 mm Hg)
before PSM and a 65% decreased risk after matching.
However, apart from grade 1 patients, the use of HOT
did not show a statistically signiﬁcant association with
hospital admission before or after matching in grade 2
patients. Also, in grade 3 and ‘no grade’ COPD patients
(predicted FEV1 ≤40% or PaO2 ≤65 mm Hg, and pre-
dicted FEV1 or PaO2 unknown), HOT was associated
with an increased risk of hospital admission before PSM.
In Korea, HOT can be prescribed by pulmonologists
as well as internists and thoracic surgery specialists based
on the results of a single arterial blood gas analysis.
Similar to the criteria used in most other countries, the
indications for reimbursement for HOT are PaO2
≤55 mm Hg or SpO2 ≤88%. Patients with PaO2
56–60 mm Hg or SpO2 <89%, must also have congestive
heart failure, polycythaemia (haematocrit >55%) or pul-
monary hypertension to qualify during the stable period
following 3 months of conservative therapy such as medi-
cation. Physicians can prescribe for patients with grade 1
or grade 2 respiratory impairment without conducting
any other tests. If patients without a grade receives a
HOT prescription, then that patient was seen by a phys-
ician under the COPD code but did not ﬁll out the
necessary form to receive an assigned grade. Hence the
patient’s clinical status fulﬁls the indications for HOT
prescription and so may in fact belong to any of the
grades described above, including grade 1. Therefore, in
patients without a grade, the use of HOT means that
they may have conditions that are clinically more severe
than those who do not use HOT.
Our results are comparable to the ﬁndings of previous
studies. We could not distinguish between PaO2 and pre-
dicted FEV1 predicted. We could only infer patients’
PaO2, FEV1 or shortness of breath according to respira-
tory impairment grade. However, for grade 1 patients
with PaO2 ≤55 mm Hg or predicted FEV1 ≤25%, use of
HOT was associated with a reduced risk of hospital
admission. Most previous studies have shown a consistent
tendency in patients with severe hypoxaemia (PaO2
<8.0 kPa) in whom HOT was associated with decreased
hospital admissions. However, Ringbaek et al15 found
that HOT did not reduce hospitalisation in patients with
moderate hypoxaemia (PaO2 >8.0 kPa). In addition,
many previous studies have found that FEV1% predicted
could be a predictor of acute exacerbation hospitalisa-
tion.20–22 One recent paper suggested that oxygen use
outside the National Institute for Health and Care
Table 2 Incidence rate for hospital admission according to use of home oxygen therapy
Respiratory impairment rating*
Before matching After matching (1:1)
Yes No Yes No Yes No Yes No
N=1330 N=35 431 ID† ID† N=1239 N=1239 ID† ID†
Grade 1
Total number of hospital admissions 416 748 0.60 1.01 244 319 0.62 0.79
Person-years 694.1 743.3 390.8 406.0
Grade 2
Total number of hospital admissions 358 601 0.61 0.63 291 128 0.59 0.37
Person-years 585.6 953.4 495.9 341.4
Grade 3
Total number of hospital admissions 245 672 0.47 0.46 245 81 0.47 0.23
Person-years 517.8 1455.4 517.8 348.3
No grade
Total number of hospital admissions 1409 9286 0.34 0.05 1409 322 0.34 0.07
Person-years 4123.0 184 555.3 4123.0 4837.3
*Grade 1 patients were defined as having chronic respiratory failure requiring oxygen therapy and an FEV1 ≤25% predicted or resting PaO2
≤55 mm Hg (room air); grade 2 patients were defined as having dyspnoea when walking at home and an FEV1 ≤30% predicted or PaO2
56–60 mm Hg (room air); grade 3 patients were defined as having dyspnoea when walking at their own pace on level ground and FEV1 ≤40%
predicted or PaO2 61–65 mm Hg (room air); ‘no grade’ was defined as predicted FEV1 or PaO2 unknown.
†Calculated total number of hospital admissions divided into sum of person-years.
ID, incidence rate.
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Excellence (NICE) guidance did not appear to prevent
admissions23 and predicted FEV1 was the only signiﬁcant
predictor of readmission.16 In South Korea, although
HOT is used according to NICE guidelines, HOT was
not associated with decreased risk of hospital admission
even in grade 2 patients (PaO2 56–60 mm Hg or pre-
dicted FEV1 ≤30%). In grade 3 or ‘no grade’ patients,
admission to hospital was more likely in HOT users
before matching, while after matching, there was no stat-
istically signiﬁcant difference in grade 3 patients. There
are two possible explanations for this result. One is that
because admission for exacerbation is more common in
severe COPD24 patients and in oxygen users,25 hospital
admissions are more frequently expected in HOT users
as they have more severe lung disease. The second possi-
bility may be explained through residual confounding.
Garcia-Aymerich et al26 showed that the risk of readmis-
sion was high in LTOT users after adjustment for severity
variables such as predicted FEV1 or PaO2. The authors
explained these results using residual confounding, in
Table 3 Relative risk for hospital admission stratified according to respiratory disability grade calculated using a negative
binomial regression model
Characteristics Relative risk (95% CI)
Grade 1 Grade 2 Grade 3 No grade
Age (years) 1.002 (0.993 to 1.010) 0.992 (0.983 to 1.001) 1.010 (0.993 to 1.021) 1.006 (1.004 to 1.009)***
Sex
Male 1.06 (0.87 to 1.29) 1.25 (0.96 to 1.62) 0.94 (0.75 to 1.18) 1.16 (1.10 to 1.23)***
Female 1.00 1.00 1.00 1.00
Health insurance type
National health
insurance
1.00 (0.80 to 1.25) 0.94 (0.75 to 1.17) 0.60 (0.49 to 0.75)*** 0.69 (0.65 to 0.73)***
Medical aid 1.00 1.00 1.00 1.00
Home oxygen therapy
Yes 1.00 1.00 1.00 1.00
No 1.27 (1.01 to 1.60)* 0.96 (0.75 to 1.22) 0.74 (0.58 to 0.93)* 0.65 (0.60 to 0.70)***
Charlson Comorbidity Index†
0 1.00 1.00 1.00 1.00
1 0.86 (0.66 to 1.13) 1.00 (0.72 to 1.39) 0.82 (0.57 to 1.17) 1.00 (0.93 to 1.07)
≥2 1.12 (0.84 to 1.49) 1.11 (0.81 to 1.53) 0.90 (0.67 to 1.21) 1.11 (1.02 to 1.21)*
ICU use
Yes 1.13 (0.74 to 1.70) 1.05 (0.42 to 2.59) 0.31 (0.09 to 1.09) 1.02 (0.82 to 1.27)
No 1.00 1.00 1.00 1.00
Number of hospital admissions
0 1.00 1.00 1.00 1.00
1 1.65 (1.29 to 2.11)*** 1.45 (1.12 to 1.88)** 1.24 (0.98 to 1.57) 1.69 (1.58 to 1.81)***
≥2 1.73 (1.34 to 2.24)*** 1.48 (1.11 to 1.96)** 1.65 (1.28 to 2.12)*** 2.04 (1.88 to 2.21)***
Grade 1 patients were defined as having chronic respiratory failure requiring oxygen therapy and an FEV1 ≤25% predicted or resting PaO2
≤55 mm Hg (room air); grade 2 patients were defined as having dyspnoea when walking at home and an FEV1 ≤30% predicted or PaO2
56–60 mm Hg (room air); grade 3 patients were defined as having dyspnoea when walking at their own pace on level ground and FEV1 ≤40%
predicted or PaO2 61–65 mm Hg (room air); ‘no grade’ was defined as predicted FEV1 or PaO2 unknown.
*p<0.05; **p<0.01; ***p <0.001.
†Calculated comorbidity component; subtracted age scores.
ICU, intensive care unit.
Table 4 Relative risk for hospital admission after propensity score matching calculated using a negative binomial regression
model
Characteristics
Relative risk (95% CI)
Grade 1 Grade 2 Grade 3 No grade
Home oxygen therapy
Yes 1.00 1.00 1.00 1.00
No 1.65 (1.25 to 2.18)*** 1.07 (0.80 to 1.43) 0.72 (0.5 to –1.02) 0.73 (0.62 to 0.86)***
Grade 1 patients were defined as having chronic respiratory failure requiring oxygen therapy and an FEV1 ≤25% predicted or resting PaO2
≤55 mm Hg (room air); grade 2 patients were defined as having dyspnoea when walking at home and an FEV1 ≤30% predicted or PaO2
56–60 mm Hg (room air); grade 3 patients were defined as having dyspnoea when walking at their own pace on level ground and FEV1 ≤40%
predicted or PaO2 61–65 mm Hg (room air); ‘no grade’ was defined as FEV1 or PaO2 unknown.
*p<0.05; **p<0.01; ***p<0.001.
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that the excess risk of COPD re-admission associated
with medical care related factors might be partially due
to confounding by indication. Our ﬁndings suggest that
HOT use reduces hospitalisation in COPD patients with
severe hypoxaemia (PaO2 ≤55 mm Hg) and a predicted
FEV1 of ≤25%. However, although HOT may improve
quality of life and help breathing during activities in
COPD patients without severe hypoxaemia, use of HOT
should be considered to prevent hospital admissions in
COPD patients with PaO2 >55 mm Hg or a predicted
FEV1 >25% . Further research on the cost-effectiveness
for HOT use in these patients is required and the cri-
teria for HOT prescription may need to be modiﬁed.
This study has several limitations. First, because we
used claims data, which are based on information in the
KNHIS claims database, we were not able to assess some
factors that could potentially inﬂuence hospital admis-
sions. For example, we had no data on smoking history,
body mass index, health behaviours, use of systemic cor-
ticosteroids, laboratory results, etc. Second, we cate-
gorised respiratory impairment into four respiratory
disability grades, as determined by predicted FEV1, PaO2
and dyspnoea. Therefore, we did not use quantitative
predicted FEV1 or PaO2 values, instead estimating a
patient’s hypoxemic status. Especially in the ‘no grade’
group, it is possible that patients with different severity
were grouped together. The third limitation is the accur-
acy of our COPD diagnosis. The accuracy of diagnoses
in KNHIS claims data is roughly 70%.27 To increase
accuracy, a review of all prescriptions would be required.
Unfortunately, we could not perform such a review here.
However, the accuracy of COPD diagnoses in this study
may have been compromised. The fourth limitation
involves the deﬁnition of newly diagnosed patients. In
this study, newly diagnosed patients were deﬁned as
those who did not have COPD claims in 2002–2004 but
did have a COPD claim in 2005. Thus, patients diag-
nosed before 2002 who did not utilise COPD-related
medical services in 2002–2004 may have been included
in the sample. The ﬁnal limitation is related to patterns
of HOT use. Although all our study subjects used HOT
in or after 2006 and we adjusted for the number of hos-
pital admission at baseline, because previous studies
hypothesized that an effect of oxygen therapy in patients
who start HOT as outpatients is less likely to be derived
from a ‘regression to the mean phenomenon’,12 we did
not know the duration of usage per day, whether use was
continuous or non-continuous, or whether patient com-
pliance was good.
Despite these limitations, our study has several
strengths. First, we analysed COPD patients using nation-
wide claims data and conducted a longitudinal
population-based prospective analysis based on claims
from 2005 to 2012. Our study population was relatively
large and our follow-up period was relatively long com-
pared to previous studies evaluating the association
between oxygen therapy and hospitalisation.12 28
Second, we were able to increase the homogeneity of
our study sample by identifying patients who were newly
diagnosed in 2005. We could observe the progression of
their disease over time via hospital admissions. Finally,
we made an effort to accurately determine the net effect
of HOT via PSM.
In conclusion, HOT reduces hospital admission risk in
COPD patients with severe hypoxaemia or a predicted
FEV1 of ≤25%. However, except for these patients, HOT
use is not associated with hospital admissions, or an
increase in the likelihood of hospital admission. Further
research on the cost-effectiveness of HOT in patients
who do not meet the indications for HOT is needed.
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